AC Immune SA Ano de IPO
Qual é o Ano de IPO de AC Immune SA?
O Ano de IPO de AC Immune SA é 2016
Qual é a definição de Ano de IPO?
A oferta pública inicia (OPI)l é um tipo de oferta pública em que as ações de uma empresa geralmente são vendidas a investidores institucionais que, por sua vez, vendem para o público em geral, em uma bolsa de valores, pela primeira vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Ano de IPO de empresas na Setor Health Care em NASDAQ em comparação com AC Immune SA
O que AC Immune SA faz?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Empresas com ano de ipo semelhantes a AC Immune SA
- The Toronto-Dominion Bank PFD SER 9 3.7% tem Ano de IPO de 2015
- Fura Gems tem Ano de IPO de 2015
- Hostess Brands tem Ano de IPO de 2015
- Nabriva Therapeutics Plc tem Ano de IPO de 2015
- REF tem Ano de IPO de 2015
- H-Source tem Ano de IPO de 2015
- AC Immune SA tem Ano de IPO de 2016
- American Pacific Borates tem Ano de IPO de 2017
- Razer tem Ano de IPO de 2017
- DEAG Deutsche Entertainment Aktiengesellschaft tem Ano de IPO de 2017
- Hamilton Beach Brands Co tem Ano de IPO de 2017
- Artelo Biosciences tem Ano de IPO de 2017
- VARTA AG tem Ano de IPO de 2017